

Nasdaq: KE

52 Week Low-High	\$21.01- \$32.00
Shares Outstanding	24.0M
Free Float	23.4M
Market Cap	~\$666M
Avg. Daily Volume (3 mo.)	191,920
Insider Holdings	~2.4%

FISCAL 2026

Revenue	\$1,431M
Adjusted EBITDA ⁽¹⁾	\$104M
EPS	\$1.13
Net Debt ⁽¹⁾	\$27M
EV/EBITDA	6.1x
Employees	~5,600

GLOBAL PRESENCE

NORTH AMERICA | EUROPE | ASIA




11 GLOBAL LOCATIONS

North America -
Jasper, Indiana (Manufacturing and World Headquarters)
Indianapolis, Indiana
Reynosa, Mexico


Europe -
Poznan, Poland
Timisoara, Romania
Tilburg, The Netherlands
Amsterdam, The Netherlands

Asia -
Nanjing, China
Laem Chabang, Thailand
Pune, India

REVENUE AND EPS



CAPITAL ALLOCATION



About Kimball Electronics


Kimball Electronics (KE) is a global, multifaceted solutions provider of **Electronics Manufacturing Services (EMS)** and **Contract Development Manufacturing Organization (CDMO)** recognized for excellence and leadership in highly regulated and complex industries.

Founded in 1961 and incorporated in 1998, the Company spun off from its parent, Kimball International, in 2014 as a standalone, public company. As it celebrates 65 years of excellence, the Company has announced its intention to rebrand as **Kimball Solutions**, reflecting its continued evolution and expanded capabilities.

KE provides integrated manufacturing services, medical disposables, drug delivery solutions, precision molded plastics, and end-to-end product lifecycle support.

Diversified Portfolio of End Markets

Fiscal 2026 Revenue



Representative Customers

nexteer



Mando

brose
Technik für Automobile

PHILIPS

REACTHEALTH

ZOLL
Advancing Resuscitation

kaléo

RegalRexnord

TRANE
TECHNOLOGIES

GRUNDFOS



Capital Allocation Strategy

- Invest in growth, with capital deployment focused on the medical CDMO portfolio
- Pursue tuck-in M&A to add capabilities, end-markets, customers, and geographic reach – particularly in medical
- Acquired Helvoet Polymer Technologies in July 2026, which expands medical CDMO platform into high-growth microfluidics, diagnostics and drug delivery, adds to European footprint and entry to India, and U.S. cross-selling opportunities
- Return capital to shareowners through disciplined share repurchases

Investment Highlights

- Sharpened strategic focus** through portfolio rationalization - divested non-core AT&M; integrated medical CDMO into EMS, and improved utilization via Tampa closure
- Regulatory & operational strength** - deep compliance, resilient supply and cold-chain, globally integrated SAP platform
- Strong liquidity profile** - debt well below peak, ten quarters of positive cash from operations, over \$400M short-term liquidity
- Margin upside** - cost alignment, higher utilization, and mix shift toward growing, higher-margin medical revenue
- Durable customer base** - 7-10 year programs; 77% of revenue from 10+ year customers supporting recurring visibility

Company Contact

Andrew D. Regrut
VP, Investor Relations, Strategic Development and Treasurer
Phone: (812) 827-4151
Email: andy.regrut@kmbi.com

Analyst Coverage

Analyst
Mike Crawford
Brett Fishbin
Max Michaelis
Derek Soderberg
Anja Soderstrom

Firm
B.Riley
KeyBanc
Lake Street
Cantor Fitzgerald
Sidoti